These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37210771)

  • 21. PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features.
    Raghavan SS; Wang JY; Kwok S; Rieger KE; Novoa RA; Brown RA
    J Cutan Pathol; 2020 Dec; 47(12):1123-1131. PubMed ID: 32700786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic Lesions.
    Lezcano C; Jungbluth AA; Busam KJ
    Surg Pathol Clin; 2021 Jun; 14(2):165-175. PubMed ID: 34023098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PRAME Immunohistochemical Expression and TERT Promoter Mutational Analysis as Ancillary Diagnostic Tools for Differentiating Proliferative Nodules From Melanoma Arising in Congenital Nevi.
    Boutko A; Hagstrom M; Lampley N; Roth A; Olivares S; Dhillon S; Fumero-Velázquez M; Benton S; Zhao J; Zhang B; Dittmann D; Asadbeigi S; Busam KJ; Gerami P
    Am J Dermatopathol; 2023 Jul; 45(7):437-447. PubMed ID: 37338065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PRAME Expression in Cancer. A Systematic Immunohistochemical Study of >5800 Epithelial and Nonepithelial Tumors.
    Kaczorowski M; Chłopek M; Kruczak A; Ryś J; Lasota J; Miettinen M
    Am J Surg Pathol; 2022 Nov; 46(11):1467-1476. PubMed ID: 35973038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort.
    Lamas NJ; Lassalle S; Martel A; Nahon-Estève S; Macocco A; Zahaf K; Lalvee S; Fayada J; Lespinet-Fabre V; Bordone O; Pedeutour F; Baillif S; Hofman P
    Pathology; 2023 Dec; 55(7):929-944. PubMed ID: 37863710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The utility of PRAME staining in identifying malignant transformation of melanocytic nevi.
    Lohman ME; Steen AJ; Grekin RC; North JP
    J Cutan Pathol; 2021 Jul; 48(7):856-862. PubMed ID: 33433032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Analysis of PRAME Expression in 127 Acral and Nail Melanocytic Lesions.
    Santandrea G; Valli R; Zanetti E; Ragazzi M; Pampena R; Longo C; Lai M; Piana S; Cesinaro AM
    Am J Surg Pathol; 2022 May; 46(5):579-590. PubMed ID: 35275883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemistry for PRAME in Dermatopathology.
    Lezcano C; Jungbluth AA; Busam KJ
    Am J Dermatopathol; 2023 Nov; 45(11):733-747. PubMed ID: 37856737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic utility of PRAME expression by immunohistochemistry in subungual and non-subungual acral melanocytic lesions.
    Rothrock AT; Torres-Cabala CA; Milton DR; Cho WC; Nagarajan P; Vanderbeck K; Curry JL; Ivan D; Prieto VG; Aung PP
    J Cutan Pathol; 2022 Oct; 49(10):859-867. PubMed ID: 35794643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PRAME immunohistochemistry of spitzoid neoplasms.
    Koh SS; Lau SK; Scapa JV; Cassarino DS
    J Cutan Pathol; 2022 Aug; 49(8):709-716. PubMed ID: 35488519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diffuse PRAME Expression Is Highly Specific for Thin Melanomas in the Distinction from Severely Dysplastic Nevi but Does Not Distinguish Metastasizing from Non-Metastasizing Thin Melanomas.
    Gassenmaier M; Hahn M; Metzler G; Bauer J; Yazdi AS; Keim U; Garbe C; Wagner NB; Forchhammer S
    Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analyses of molecular and histopathologic features and expression of PRAME by immunohistochemistry in mucosal melanomas.
    Toyama A; Siegel L; Nelson AC; Najmuddin M; Bu L; LaRue R; Henzler C; Caicedo-Granados E; Giubellino A; Li F
    Mod Pathol; 2019 Dec; 32(12):1727-1733. PubMed ID: 31375769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Performance of preferentially expressed antigen in melanoma (PRAME) immunohistochemistry for metastatic melanoma in cytology specimens.
    Saad M; Cantley R; Hao W; Wang Z; Thomas D; Pantanowitz L; Jin X
    Diagn Cytopathol; 2024 Jul; 52(7):362-368. PubMed ID: 38558495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemistry for PRAME in the Distinction of Nodal Nevi From Metastatic Melanoma.
    Lezcano C; Pulitzer M; Moy AP; Hollmann TJ; Jungbluth AA; Busam KJ
    Am J Surg Pathol; 2020 Apr; 44(4):503-508. PubMed ID: 31633488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas.
    Field MG; Durante MA; Decatur CL; Tarlan B; Oelschlager KM; Stone JF; Kuznetsov J; Bowcock AM; Kurtenbach S; Harbour JW
    Oncotarget; 2016 Sep; 7(37):59209-59219. PubMed ID: 27486988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preferentially expressed Antigen in MElanoma immunohistochemistry as an adjunct for evaluating ambiguous melanocytic proliferation.
    Fattori A; de la Fouchardière A; Cribier B; Mitcov M
    Hum Pathol; 2022 Mar; 121():19-28. PubMed ID: 34990622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms.
    McBride JD; McAfee JL; Piliang M; Bergfeld WF; Fernandez AP; Ronen S; Billings SD; Ko JS
    J Cutan Pathol; 2022 Mar; 49(3):220-230. PubMed ID: 34476825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. COMPREHENSIVE MOLECULAR PROFILING OF UVEAL MELANOMA EVALUATED WITH GENE EXPRESSION PROFILING, PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA EXPRESSION, AND NEXT-GENERATION SEQUENCING.
    Alsoudi AF; Skrehot HC; Chévez-Barrios P; Divatia M; De La Garza M; Bretana ME; Schefler AC
    Retina; 2024 Sep; 44(9):1580-1589. PubMed ID: 39167579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ki67 is a better marker than PRAME in risk stratification of BAP1-positive and BAP1-loss uveal melanomas.
    Donizy P; Spytek M; Krzyziński M; Kotowski K; Markiewicz A; Romanowska-Dixon B; Biecek P; Hoang MP
    Br J Ophthalmol; 2024 Jun; 108(7):1005-1010. PubMed ID: 37734766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pitfalls of PRAME Immunohistochemistry in a Large Series of Melanocytic and Nonmelanocytic Lesions With Literature Review.
    Turner N; Ko CJ; McNiff JM; Galan A
    Am J Dermatopathol; 2024 Jan; 46(1):21-30. PubMed ID: 37982498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.